Annual Report 2019

CORPORATE CALENDAR OF 019 3 The United Laboratories International Holdings Limited Annual Report 2019 August • The United Laboratories was awarded “2018 China Pharmaceutical Industry Top 100 Companies” (ranking the 22nd) by China National Pharmaceutical Industry Information Center. • The United Laboratories and Evergrande (Chengdu) entered into the Investment and Cooperation Agreement with respect to the equity interest of United Laboratories (Chengdu) and development of the Land. September • Insulin degludee injection of The United Laboratories was approved for clinical trial. • Zhuhai United Laboratories was listed in the fourth batch of national green plant models issued by the Ministry of Industry and Information Technology. October • Zhuhai United Laboratories was awarded “2019 China Pharmaceutical Industry Top 100 Companies with Comprehensive Strength” (ranking the 18th) and “Leading Export Brand of Bulk Medicine of China’s Pharmaceutical Industry” by China Pharmaceutical Industry Association. November • The United Laboratories entered into a facility agreement for dual currency syndicated loans in the amount equivalent to up to HK$2 billion for a term of three years. • The Quality Control Center of Zhuhai United Laboratories passed the certification of China National Accreditation Service for Conformity Assessment (CNAS) for a second time. • “Study on Quality and Efficacy Consistency Evaluation of Amoxicillin Capsule (0.25g) and Cefuroxime Axetil Tablet (0.25g)” was named Zhongshan Healthcare Industry Development Project 2019 and granted financial subsidies. December • “Technology Development of New Drug for Rheumatoid Arthritis Treatment” was named Zhongshan 4th Batch of Specially-Funded Technology Development Project 2019 and granted financial subsidies.